- Home
- UHG vs TECX Comparison
UHG vs TECX Comparison
Compare UHG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- TECX
- Stock Information
- Founded
- UHG 2004
- TECX 2019
- Country
- UHG United States
- TECX United States
- Employees
- UHG N/A
- TECX N/A
- Industry
- UHG Homebuilding
- TECX
- Sector
- UHG Consumer Discretionary
- TECX
- Exchange
- UHG Nasdaq
- TECX Nasdaq
- Market Cap
- UHG 152.4M
- TECX 334.4M
- IPO Year
- UHG N/A
- TECX 2018
- Fundamental
- Price
- UHG $2.91
- TECX $19.91
- Analyst Decision
- UHG
- TECX Buy
- Analyst Count
- UHG 0
- TECX 6
- Target Price
- UHG N/A
- TECX $78.67
- AVG Volume (30 Days)
- UHG 277.6K
- TECX 244.3K
- Earning Date
- UHG 08-07-2025
- TECX 08-13-2025
- Dividend Yield
- UHG N/A
- TECX N/A
- EPS Growth
- UHG N/A
- TECX N/A
- EPS
- UHG 0.76
- TECX N/A
- Revenue
- UHG $449,877,017.00
- TECX N/A
- Revenue This Year
- UHG N/A
- TECX N/A
- Revenue Next Year
- UHG N/A
- TECX N/A
- P/E Ratio
- UHG $3.95
- TECX N/A
- Revenue Growth
- UHG 5.24
- TECX N/A
- 52 Week Low
- UHG $1.60
- TECX $13.70
- 52 Week High
- UHG $6.93
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- UHG 65.55
- TECX 43.97
- Support Level
- UHG $3.19
- TECX $17.97
- Resistance Level
- UHG $3.70
- TECX $20.75
- Average True Range (ATR)
- UHG 0.35
- TECX 1.40
- MACD
- UHG -0.02
- TECX -0.36
- Stochastic Oscillator
- UHG 63.53
- TECX 26.93
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.